Home
    Welcome Note
    Registration
    Accommodation
    Contact Us
     Home
     Welcome Note
     Congress Chairpersons
     Committees
     Faculty
     Timetable
     Scientific Program
         Congress Presentations
     Leukemia Supplements
     Abstract Submission
         Poster Presentations
         Poster Guidelines
     CME Accreditation
         CME - EACCME
         EHA - CME
     Registration
         Invitation Letter
     Accommodation
         Andel’s Hotel Berlin
     Sponsorship & Exhibition
         Sponsors
         Exhibitors
     General Information
         Before You Travel...
         Tips and Hints
         Italian Agent
     About Berlin
     Endorsement
     Partners
  
The International Congress on
Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Andel’s Hotel, Berlin, Germany, September 8-11, 2011
 
  Scientific Program Print

Thursday, September 8, 2011
19:00-20:30 Welcome Reception
   
Friday, September 9, 2011
HALL A
08:30-10:00
Plenary Session 1
SCT in Myeloma and MDS
Chairs: N. Kröger, Germany & A. Nagler, Israel
08:30-08:35 Co-Chairpersons Introduction
   
Autologous SCT as first line treatment?
08:35-08:45 Yes: J.L. Harousseau, France
08:45-08:55 No: J. Blade, Spain
08:55-09:15 Discussion
    
Allo SCT in elderly patients (>60 y) with MDS
09:15-09:30 Yes: N. Kröger, Germany
09:30-09:45 No: H.J. Deeg, USA
09:45-10:00 Discussion
 
   
10:00-10:30
Coffee Break
   
10:30-12:00
Session 2
Relapse Prevention
Relapse prevention: Prophylactic DLI?
Chair: A.R. Zander, Germany
10:30-10:45 Yes: H.J. Kolb, Germany
10:45-11:00 No: A. Bacigalupo, Italy
11:00-11:15 Discussion
       
Can we prevent relapse by novel conditioning regimen?
Chair: S.A. Giralt, USA
11:15-11:30 Yes: M. de Lima, USA 
11:30-11:45 No: A. Shimoni, Israel
11:45-12:00 Discussion
  
12:00-13:00
Lunch Break
   
13:00-13:45
Special Debate: Is there any place for the prophylactic collection of autologous stem cells for major radiation incidents?
Chair: A. Madrigal, UK
13:00-13:05 No: D. Niederwieser, Germany
13:05-13:10 Yes: A.S. Shimosaka, Japan
13:10-13:15 No: D.M. Weinstock, USA
13:15-13:20 Yes: R. Powles, UK
13:20-13:25 No:  A. Buzyn, France
13:25-13:45 Discussion
     
13:45-14:00
Break
 
14:00-15:30
Session 4
Treatment and Prevention of Relapse
Second allo for relapse
Chair: J. Miller, USA
14:00-14:15 Yes: S. Slavin, Israel
14:15-14:30 No: S.A. Giralt, USA
14:30-14:45 Discussion
  
Donor selection to prevent relapse
Chair: M. de Lima, USA
14:45-15:00 According to KIR typing: J. Miller, USA 
15:00-15:15 According to HLA typing: A. Madrigal, UK
15:15-15:30 Discussion
     
15:30-16:00
Coffee Break
    
16:00-17:30
Session 6
Refractory and Residual Leukemia
Allo SCT for refractory leukemia
Chair: J.M. Rowe, Israel
16:00-16:15 Yes: M. Mohty, France
16:15-16:30 No: D. Blaise, France
16:30-16:45 Discussion
   
Should all MRD positive patients receive allo SCT?
Chair: C. Peters, Austria
16:45-17:00 Yes: P. Bader, Germany
17:00-17:15 No: G. Henze, Germany
17:15-17:30 Discussion
     
HALL B
10:30-12:00
Session 3
AML and CML
Indication for unrelated allo SCT in 1. CR AML
Chair: M. Mohty, France
10:30-10:45 Yes: D. Niederwieser, Germany
10:45-11:00

No: I. Yakoub-Agha, France

11:00-11:15 Discussion
   
Allogeneic SCT for CML after failure to 1. TKI
Chair: R. Hehlmann, Germany
11:15-11:30 Yes: E. Olavarria, Spain 
11:30-11:45 No: J.F. Apperley, UK
11:45-12:00 Discussion
     
12:00-13:00
Lunch Break
      
14:00-15:30
Session 5
Aplastic Anemia and Autoimmune Diseases
MUD or immunsuppressive therapy for aplastic anemia
Chair: J. Finke, Germany
14:00-14:15 MUD: J.R. Passweg, Switzerland
14:15-14:30 IS: A. Bacigalupo, Italy
14:30-14:45 Discussion
   
Autologous SCT for autoimmune disease
Chair: R. Arnold, Germany
14:45-15:00 Yes: D. Farge-Bancel, France
15:00-15:15 No: S. Dabadghao, India
15:15-15:30 Discussion
    
15:30-16:00
Coffee Break
  
16:00-17:30
Session 7
GvHD Prevention by T-Cell Modulation
Can Treg prevent GvHD without losing GvL?
Chair: E. Holler, Germany
16:00-16:15 Yes: M.F. Martelli, Italy
16:15-16:30 No:J.L. Ferrara, USA
16:30-16:45 Discussion
  
Is photopheresis treatment of choice for cGvHD?
Chair: H.J. Deeg, USA
16:45-17:00 Yes: H. Greinix, Austria
17:00-17:15 No: G. Socié, France
17:15-17:30 Discussion
    
Saturday, September 10, 2011
HALL A
08:30-10:00
Session 8
Cord Blood
Is double cord blood to be preferred to a single unit?
Chair: E. Gluckman, France
08:30-08:45 Yes: C. Brunstein, USA
08:45-09:00 No: V. Rocha, France
09:00-09:15 Discussion
   
Should cord blood unit be selected according to HLA or cell-based?
Chair: V. Rocha, France 
09:15-09:30 Cell-based: E. Gluckman, France
09:30-09:45 HLA-based: C. Brunstein, USA
09:45-10:00 Discussion
   
10:00-10:30
Coffee Break
    
10:30-12:00
Session 10
Donor Selection
Which is the donor of choice if no MUD is available?
Chair: A. Madrigal, UK
10:30-10:45 Haplo: L. Uharek, Germany
10:45-11:00 Cord blood: W. Arcese, Italy
11:00-11:15 Discussion
    
Should we expand cord blood?
Chair: W. Arcese, Italy
11:15-11:30 Yes: A. Nagler, Israel
11:30-11:45 No: V. Rocha, France
11:45-12:00 Discussion
   
12:00-12:45
Lunch Break
      
12:45-14:00
Novartis Satellite Symposium
Update and Perspectives on Iron Chelation and Immunotherapy in Transplantation
12:45-12:50 Introduction: N. Kröger, Hamburg
12:50-13:10 Pathophysiology of Acute GvHD: Innate Meets Adaptive Immunity: E. Holler, Regensburg
13:10-13:30 Does Iron Chelation Improve Survival in SCT? H. Al-Ali, Leipzig
13:30-13:50 Practical Aspects of an Iron Chelation Therapy in SCT: U. Platzbecker, Dresden
13:50-14:00 Summary and Discussion: N. Kröger, Hamburg
     
14:00-15:30
Session 12
Lymphoma
Autologous SCT in FL
Chair: P. Corradini, Italy
14:00-14:15 Yes: C. Gisselbrecht, France
14:15-14:30 No: U. Dührsen, Germany
14:30-14:45 Discussion
   
Transplantation for T-cell lymphoma
Chair: C. Gisselbrecht, France
14:45-15:00 Pro auto: P. Reimer, Germany
15:00-15:15 Pro allo: P. Corradini, Italy
15:15-15:30 Discussion
   
15:30-16:00
Coffee Break
    
16:00-17:30
Session 14
Allogeneic SCT for Myeloma and Hodgkin's Disease
Is there a place for allo SCT in treatment of MM?
Chair: N. Kröger, Germany
16:00-16:15 Yes: G. Gahrton, Sweden
16:15-16:30 No: H. Goldschmidt, Germany
16:30-16:45 Discussion
   
Is there a place for allo SCT in Hodgkin’s disease?
Chair: U. Dührsen, Germany
16:45-17:00 Yes: L. Farina, Italy
17:00-17:15 No: V. Diehl, Germany
17:15-17:30 Discussion
  
HALL B
08:30-10:00
Session 9
Myelofibrosis and Haploidentical Transplantation
Allo SCT for elderly myelofibrosis patients (>60 y)
Chair: A. Bacigalupo, Italy
08:30-08:45 Yes: N. Kröger, Germany
08:45-09:00 No: R.A. Mesa, USA
09:00-09:15 Discussion
 
Should haplo-SCT be performed with T-cell depletion?
Chair: Y. Reisner, Israel
09:15-09:30 Yes: R. Handgretinger, Germany
09:30-09:45 No: F. Ciceri, Italy
09:45-10:00 Discussion
      
10:00-10:30
Coffee Break
 
10:30-12:00
Session 11
Cell and Gene Therapy
Is specific T-cell therapy targeting mHag useful?
Chair: F. Locatelli, Italy
10:30-10:45 Yes: S. Riddell, USA
10:45-11:00 No: M. Bornhäuser, Germany
11:00-11:15 Discussion
 
Gene therapy for genetic diseases (SCID, FA, CGD)
Chair: R. Handgretinger, Germany
11:15-11:30 Yes: M. Cavazzana-Calvo, France
11:30-11:45 No: I. Müller, Germany
11:45-12:00 Discussion
      
12:00-13:00
Lunch Break
   
14:00-15:30
Session 13
T-Cell Depletion and Mesenchymal Stroma Cells
T-cell depletion and T-cell add back
Chair: L. Uharek, Germany
14:00-14:15 Yes: J.H.F Falkenburg, The Netherlands
14:15-14:30 No: R. Storb, USA
14:30-14:45 Discussion
  
MSC for GvHD
Chair: M. Bornhäuser, Germany
14:45-15:00 Yes: K. Le Blanc, Sweden
15:00-15:15 No: F. Locatelli, Italy
15:15-15:30 Discussion
  
15:30-16:00
Coffee Break
  
16:00-17:30
Session 15
GvHD Prevention by Antibodies
GvHD prevention
Chair: A.R. Zander, Germany
16:00-16:15 Pro ATG: J. Finke, Germany
16:15-16:30 Pro Alemtuzemab: S. Mackinnon, UK
16:30-16:45 Discussion
    
Is it possible to separate GvHD from GvL?
Chair: J.L. Ferrara, USA
16:45-17:00 Yes: E. Holler, Germany
17:00-17:15 No: H.J. Deeg, USA
17:15-17:30 Discussion
   
Sunday, September 11, 2011
HALL A
08:30-10:00
Session 16
Improving Transplant Outcome in Multiple Myeloma
Should CR be target of therapy in MM?
Chair: P. Sonneveld, The Netherlands
08:30-08:45 Yes: S.A. Giralt, USA
08:45-09:00 No: B. Barlogie, USA
09:00-09:15 Discussion
 
Therapy post transplantation in MM
Chair: B. Barlogie, USA
09:15-09:30 Pro consolidation: J. Blade, Spain
09:30-09:45 Pro maintenance: P. Sonneveld, The Netherlands
09:45-10:00 Discussion
  
10:00-11:00
Plenary Session 18
Fungal Resistance
Supported by an unrestricted grant from Gilead
Aspergillus resistance is only seen on the petri dish and not in the patient
10:00-10:05 Chair: N. Kröger, Germany
10:05-10:25 Pro: H. Hof, Germany
10:25-10:45 Con: G. Maschmeyer, Germany
10:45-11:00 Discussion
 
11:00-11:30
Coffee Break
   
11:30-13:00
Plenary Session 19
ALL and Intensity of Conditioning Regimen
Is there a role for allo SCT in standard risk ALL?
Chair: D. Niederwieser, Germany  
11:30-11:45 Yes: J.M. Rowe, Israel
11:45-12:00 No: D. Hoelzer, Germany
12:00-12:15 Discussion
  
Reduced or standard conditioning?
Chair: G. Ehninger, Germany
12:15-12:30 Pro reduced: R. Storb, USA
12:30-12:45 Pro standard: A. Nagler, Israel
12:45-13:00 Discussion
      
HALL B
08:30-10:00
Session 17
Infection
Should CMV infection post allo SCT be treated by cell-based therapy?
Chair: S. Riddell, USA
08:30-08:45 Yes: H. Einsele, Germany
08:45-09:00 No: P. Ljungman, Sweden
09:00-09:15
Discussion
  
Is combined antifungal therapy more efficient than single agent therapy?
Chair: H. Einsele, Germany
09:15-09:30 Yes: N. Keller, Israel
09:30-09:45 No: G. Maschmeyer, Germany
09:45-10:00 Discussion
 

Home    Contact Us   
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 06/26/2013 Created by     WebStudio.co.il